 versu sequenti chemo-endocrin therapi advanc prostat cancer final result random southwest oncolog group studi cytotox chemotherapi surviv benefit metastat prostat cancer patient far-advanc refractori diseas effect chemotherapi cours diseas southwest oncolog group swog random trial septemb octob endocrin therapi diethylstilbestrol de orchiectomi cyclophosphamide-adriamycin doxorubicin adria columbu OH chemotherapi progress initi chemo-endocrin therapi forty-thre patient inelig patient chemo-endocrin therapi arm respons rate endocrin therapi log-linear model tumor respons treatment arm stratif factor combin arm patient endocrin therapi arm object partial respons other stabl diseas differ initi respons rate time treatment failur surviv ident treatment arm seventy-seven percent patient initi endocrin therapi arm median surviv month chemo-endocrin therapi arm median surviv month signific effect treatment surviv adjust stratif variabl cox regress model exploratori surviv analys patient arm signific time treatment failur surviv advantag patient de initi endocrin therapi eighty-six percent patient orchiectomi de data addit cytotox chemotherapi initi endocrin therapi patient metastat prostat cancer